Combination Therapy With Stavudine and Didanosine in Children With Advanced Human Immunodeficiency Virus Infection: Pharmacokinetic Properties, Safety, and Immunologic and Virologic Effects
Mark W. Kline(Tulane University), Lisa M. Dunkle(Merck & Co., Inc., Rahway, NJ, USA (United States)), William T. Shearer(Baylor College of Medicine), Victoria L. Rutkiewicz(Baylor College of Medicine), Kim D. Evans(Baylor College of Medicine), Alice T. Harris(Baylor College of Medicine), Marianne E. Federici(Baylor College of Medicine), Courtney V. Fletcher(University of Nebraska at Omaha)
Cited by 31
Related Papers
Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment
|New England Journal of Medicine|1994|3.7k
Lymphocyte subsets in healthy children from birth through 18 years of age
|Journal of Allergy and Clinical Immunology|2003|828
Viral Load and Disease Progression in Infants Infected with Human Immunodeficiency Virus Type 1
|New England Journal of Medicine|1997|551
Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: The Primary Immune Deficiency Treatment Consortium experience
|Journal of Allergy and Clinical Immunology|2013|343